聚焦临床试验研究：确保新型囊性纤维化药物发挥其潜力。 - Suppr

Suppr

超能文献

Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.

作者信息

Elborn J Stuart, Davies Jane

机构信息

Royal Brompton Hospital, London SW3 6NP, UK; Imperial College, London, UK; Queen's University Belfast, Belfast, UK.

Royal Brompton Hospital, London SW3 6NP, UK; Imperial College, London, UK.

出版信息

Lancet Respir Med. 2017 Sep;5(9):681-683. doi: 10.1016/S2213-2600(17)30311-9.

DOI:10.1016/S2213-2600(17)30311-9

PMID:28853396

Abstract

摘要

相似文献

Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.

Lancet Respir Med. 2017 Sep;5(9):681-683. doi: 10.1016/S2213-2600(17)30311-9.

Cystic Fibrosis: The Dawn of a New Therapeutic Era.

Am J Respir Crit Care Med. 2017 Apr 15;195(8):979-984. doi: 10.1164/rccm.201606-1250PP.

Treating Specific Variants Causing Cystic Fibrosis.

JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.

AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.

Am J Respir Crit Care Med. 2017 May 1;195(9):1092-1099. doi: 10.1164/rccm.201702-0266ED.

The march towards CFTR modulator access for all people with CF: The end of the beginning.

J Cyst Fibros. 2021 Mar;20(2):185-187. doi: 10.1016/j.jcf.2021.01.005. Epub 2021 Jan 22.

Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.

Clin Respir J. 2018 Apr;12(4):1767-1768. doi: 10.1111/crj.12677. Epub 2017 Aug 4.

New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.

Pediatr Clin North Am. 2016 Aug;63(4):751-64. doi: 10.1016/j.pcl.2016.04.006.

Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.

Pancreas. 2020 Jul;49(6):e50-e51. doi: 10.1097/MPA.0000000000001567.

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.

Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.

Tribulations and (clinical) trials in cystic fibrosis.

J Cyst Fibros. 2021 Mar;20(2):188-190. doi: 10.1016/j.jcf.2020.12.017. Epub 2021 Jan 3.

引用本文的文献

Impact of indoor Air Pollution on the Linear growth of children in Jimma, Ethiopia.

BMC Public Health. 2024 Feb 16;24(1):488. doi: 10.1186/s12889-024-17975-3.

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease.

Pharmaceuticals (Basel). 2023 Apr 13;16(4):584. doi: 10.3390/ph16040584.

Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.

Curr Opin Pediatr. 2018 Jun;30(3):372-377. doi: 10.1097/MOP.0000000000000627.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.

作者信息

Elborn J Stuart, Davies Jane

机构信息

Royal Brompton Hospital, London SW3 6NP, UK; Imperial College, London, UK; Queen's University Belfast, Belfast, UK.

Royal Brompton Hospital, London SW3 6NP, UK; Imperial College, London, UK.

出版信息

Lancet Respir Med. 2017 Sep;5(9):681-683. doi: 10.1016/S2213-2600(17)30311-9.

DOI:10.1016/S2213-2600(17)30311-9

PMID:28853396

Abstract

摘要

相似文献

Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.

Lancet Respir Med. 2017 Sep;5(9):681-683. doi: 10.1016/S2213-2600(17)30311-9.

Cystic Fibrosis: The Dawn of a New Therapeutic Era.

Am J Respir Crit Care Med. 2017 Apr 15;195(8):979-984. doi: 10.1164/rccm.201606-1250PP.

Treating Specific Variants Causing Cystic Fibrosis.

JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823.

AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.

Am J Respir Crit Care Med. 2017 May 1;195(9):1092-1099. doi: 10.1164/rccm.201702-0266ED.

The march towards CFTR modulator access for all people with CF: The end of the beginning.

J Cyst Fibros. 2021 Mar;20(2):185-187. doi: 10.1016/j.jcf.2021.01.005. Epub 2021 Jan 22.

Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.

Clin Respir J. 2018 Apr;12(4):1767-1768. doi: 10.1111/crj.12677. Epub 2017 Aug 4.

New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.

Pediatr Clin North Am. 2016 Aug;63(4):751-64. doi: 10.1016/j.pcl.2016.04.006.

Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.

Pancreas. 2020 Jul;49(6):e50-e51. doi: 10.1097/MPA.0000000000001567.

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.

Pediatr Pulmonol. 2020 Sep;55(9):2302-2306. doi: 10.1002/ppul.24854. Epub 2020 May 26.

Tribulations and (clinical) trials in cystic fibrosis.

J Cyst Fibros. 2021 Mar;20(2):188-190. doi: 10.1016/j.jcf.2020.12.017. Epub 2021 Jan 3.

引用本文的文献

Impact of indoor Air Pollution on the Linear growth of children in Jimma, Ethiopia.

BMC Public Health. 2024 Feb 16;24(1):488. doi: 10.1186/s12889-024-17975-3.

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease.

Pharmaceuticals (Basel). 2023 Apr 13;16(4):584. doi: 10.3390/ph16040584.

Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.

Curr Opin Pediatr. 2018 Jun;30(3):372-377. doi: 10.1097/MOP.0000000000000627.